A Review of Lenalidomide in Combination with Dexamethasone for the Treatment of Multiple Myeloma

DSpace/Manakin Repository

A Review of Lenalidomide in Combination with Dexamethasone for the Treatment of Multiple Myeloma

Citable link to this page

. . . . . .

Title: A Review of Lenalidomide in Combination with Dexamethasone for the Treatment of Multiple Myeloma
Author: Hideshima, Teru; Raje, Noopur; Richardson, Paul Gerard Guy; Anderson, Kenneth Carl

Note: Order does not necessarily reflect citation order of authors.

Citation: Hideshima, Teru, Noopur Raje, Paul G. Richardson, and Kenneth C. Anderson. 2008. A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma. Therapeutics and Clinical Risk Management 4(1): 129-136.
Full Text & Related Files:
Abstract: Lenalidomide (also known as Revlimid®, CC-5013) is an immunomodulatory derivative of thalidomide and has more potent anti-tumor and anti-inflammatory effects than thalidomide. The molecular mechanisms of anti-tumor activity of lenalidomide have been extensively studied in multiple myeloma (MM) both preclinical models and in clinical trials. Lenalidomide: directly triggers growth arrest and/or apoptosis of drug resistant MM cells; inhibits binding of MM cells to bone marrow (BM) extracellular matrix proteins and stromal cells; modulates cytokine secretion and inhibits angiogenesis in the BM milieu; and augments host anti-tumor immunity. Lenalidomide achieved responses in patients with relapsed refractory MM. Moreover, lenalidomide with dexamethasone (Dex) demonstrates more potent anti-MM activities than Dex both in vitro and in randomized phase III clinical trials. Specifically, the combination improved overall and extent of response, as well as prolonged time to progression and overall survival, resulting in FDA approval of lenalidomide with Dex for therapy MM relapsing after prior therapy.
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503648/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:4621017

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters